FDA Clears Vitestro's Aletta to Draw Blood Without a Human

The Food and Drug Administration authorized Vitestro's Aletta robot on Aug. 19, 2026, the first fully autonomous device cleared in the United States to draw blood from a patient's arm without a person doing the stick. The agency used its De Novo pathway, reserved for novel devices with no existing product category, which means Aletta's authorization now sets the special controls every device of its kind will be measured against.

Vitestro, a Utrecht, Netherlands-based medical robotics company, had already CE-marked Aletta in Europe roughly two years earlier. "From our CE mark in Europe to today's FDA authorization in the U.S., this milestone reflects years of technical development," said Toon Overbeeke, Vitestro's chief executive and co-founder, in the company's announcement.

What Aletta actually does

Aletta uses near-infrared light and Doppler ultrasound to find a vein in a patient's arm, distinguishing it from nearby arteries before committing to a stick. The device then applies a tourniquet, disinfects the skin, inserts the needle, fills the collection tubes, and applies a bandage, largely without a person touching the patient. If the sensors can't identify a suitable vein, the FDA said, the device does not attempt the draw.

The authorization covers use on adults in outpatient settings only, under the oversight of a phlebotomy-trained supervisor. That supervisor doesn't have to watch one machine at a time: the label allows one person to oversee up to three Aletta units running simultaneously, which is the ratio the FDA's own justification leans on. "Blood draws are one of the most commonly performed medical procedures in the United States, yet patients may face delays due to a growing shortage of trained phlebotomists," said Michelle Tarver, director of the FDA's Center for Devices and Radiological Health, in the agency's press release.

The number behind the authorization

The clinical case for Aletta rests on a trial run in the Netherlands with more than 1,600 participants, in which the device drew blood successfully on the first attempt 94.5% of the time, according to IEEE Spectrum, which reviewed the results. That figure is the one Vitestro and outside clinicians keep coming back to, because a trained human phlebotomist's first-stick success rate is the baseline any automated system has to clear before it's worth deploying at all, not just demonstrating.

"It's exceptional performance. It's definitely as good if not better than a typical professional phlebotomist," said Joe El-Khoury, a clinical chemist at Yale, of the trial data. Max Balter, a surgical-robotics specialist at Medtronic, put it more bluntly: "You have to tip your cap to them... with their FDA clearance, it moves the whole industry forward."

Metric	Aletta	Context
First-attempt success rate	94.5%	Netherlands trial, 1,600+ patients
Supervision ratio	1 phlebotomist : 3 devices	Set by the FDA authorization
Time from CE mark to FDA clearance	~2 years	CE mark predates U.S. filing
Series B raised	$70 million	Closed in March 2026, per Fierce Biotech

What the FDA didn't publish

What's missing from the agency's own announcement is as notable as what's in it. The FDA's release describes draw rates as "comparable to or better than trained human phlebotomists" and calls adverse events "uncommon and mild," but publishes no hemolysis rate, no named trial, and no exact adverse-event percentage. Vitestro's own announcement doesn't supply those figures either, a gap hospital risk committees will likely want closed before wide rollout.

Vitestro raised a $70 million Series B round in March 2026, according to Fierce Biotech, money that funded the U.S. regulatory push now paying off. Neither the FDA nor Vitestro has said when Aletta will reach American clinics commercially; the authorization clears the device for marketing, not a rollout date, and a U.S. commercial launch follows a still-pending multicenter trial.

The pattern Aletta shares with Agility Robotics' Digit 5, another machine now priced and shipping into a labor-shortage market, is a supervisor overseeing more automation than one person could operate directly. The pitch in both cases is not that the robot replaces workers, but that it changes the ratio of workers to tasks; whether hospitals accept that ratio at Aletta's price, which neither Vitestro nor the FDA has disclosed, is the question the CE mark's two-year European run hasn't fully answered.

A De Novo grant is closer to a beginning than an end of regulatory exposure, the way NHTSA's audit of Tesla's Cybercab followed rather than preceded that vehicle's path to market. The next concrete step for Aletta is the U.S. multicenter trial Vitestro says must happen before commercial sale, one that will need to hold up under scrutiny from competing device makers and reimbursement bodies once real money is on the table.